29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS Download PDF Post navigationPreviousPrevious post:Corrective statement on the consolidated accounts as of December 31, 2023NextNext post:AB Science webcast of May 30, 2024Related PostsSummary of the webcast held on December 16, 2024December 17, 2024AB Science webcast of December 16, 2024December 16, 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETDecember 11, 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024Revenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
